The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 11, 2018

Filed:

Oct. 11, 2016
Applicants:

Duke University, Durham, NC (US);

The United States of America As Represented BY the Secretary of Health and Human Services, National Institutes of Health, Washington, DC (US);

Inventors:

Darell D. Bigner, Mebane, NC (US);

Chien-Tsun Kuan, Cary, NC (US);

Ira H. Pastan, Potomac, MD (US);

Charles Pegram, Durham, NC (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 14/21 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 39/39558 (2013.01); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); C07K 14/21 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/92 (2013.01); C07K 2319/04 (2013.01); C07K 2319/55 (2013.01);
Abstract

We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.


Find Patent Forward Citations

Loading…